Not Yet RecruitingPhase 2

A Dose Finding Study of IBI3016 in Mild to Moderate Hypertensive Patients

China352 participantsStarted 2026-02-06

Plain-language summary

The purpose of this study is to evaluate the efficacy, safety and tolerability of IBI3016 or placebo, given subcutaneously, every 3 or 6 months, at different dose levels in patients with mild to moderate hypertension

Who can participate

Age range18 Years – 75 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Signed informed consent.
✓. Males or females aged 18 to 75 years.
✓. Diagnosis of primary hypertension without anti-HTN medication or with one anti-HTN medication
✓. Mean sitting SBP ≥140 mmHg and \< 170 mmHg measured by OBPM.
✓. Participants able to understand and comply with study procedures.

Exclusion criteria

✕. Known history of secondary hypertension.
✕. Orthostatic hypotension.
✕. Laboratory parameter assessments outside of range at screening：
✕. Medical condition, other than hypertension, requiring treatment with RAAS inhibitor.
✕. Current or history of intolerance to ACEi and/or ARBs.
✕. Acute myocardial infarction (AMI), unstable angina, percutaneous coronary intervention (PCI) , coronary artery bypass graft (CABG), ischemic or hemorrhagic stroke, transient ischemic attack, or clinically significant cardiac arrhythmias within 6 months prior to screening. Any history of congestive heart failure.

What they're measuring

Change in SBP by OBPM

Timeframe: From baseline through month 3

Trial details

NCT IDNCT07352969

SponsorInnovent Biologics (Suzhou) Co. Ltd.

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2029-03-27

Contact for this trial

Jinling Fan

0512-69566088 jinling.fan@innoventbio.com

View on ClinicalTrials.gov More Hypertension trials